News
ERA-EDTA, May 24-27, Paris, France
May 08 2012
BioPorto Diagnostics Product overview 2012
March 02 2012
ISICEM 2012, March 20-23, Brussels, Belgium
February 23 2012
CRITICARE, February 15-19, Pune, India
January 24 2012
Conference on Continuous Renal Replacement Therapies (CRRT), February 12-15, San Diego, USA
January 24 2012
MEDLAB, Arab Health, January 23-26, Dubai, UAE
January 16 2012
An addition to the Obesity and Type 2 Diabetes antibody portfolio
December 22 2011
Better kidney markers ahead?
December 05 2011
New NGAL.com website launched
November 24 2011
MEDICA, November 16-19, Düsseldorf, Germany
October 26 2011
ESICM 2011, October 1-5, Berlin, Germany
September 06 2011 by Bioporto Diagnostics
Bioporto Diagnostics is exhibiting at the 24th Annual Congress of the European Society of Intensive Care Medicine.
Over 5,400 participants will gather to learn the latest intensive care medicine findings in a growing event with more than 60 exhibitors, 20 satellite symposia and over 1,300 submitted abstracts.
BioPorto Diagnostic will be promoting The NGAL Test™, a test measuring the emerging kidney biomarker; NGAL. The NGAL Test™ is CE IVD registered for diagnostic use in Europe and Canada, and available for research use only in the United States.The NGAL Test™ is currently pending FDA clearance for diagnostics use in the United States.
What is NGAL?
NGAL is a biomarker for diagnosing acute kidney injury (AKI). The biomarker has been recognised by the market as a new way to identify patients at risk of developing potentially severe acute kidney injury (AKI).
Meet Jakob Ohm Eriksen, Product Manager joe@bioporto.com and Klaus Boberg Pedersen, Product Manager kbp@bioporto.com at our booth no. 70 in hall 15.1.
For further information please visit:http://www.esicm.org/Data/ModuleGestionDeContenu/PagesGenerees/07-congresses/0A-annual-congress/105.asp
